A total of 2753 strains of shigella belonging to subgroups A, B, and C that were isolated from patients in England and Wales during the period from 1979 to mid-1983 were studied. Of these, 1690 The proportion of patients with recent foreign contact was notably smaller among those with strains resistant to trimethoprim than among those with strains sensitive to trimethoprim. The increase in resistance to trimethoprim might partly result from the use in Britain of compounds containing trimethoprim for the treatment of shigellosis.
Introduction
Infections caused by Shigella dysenteriae, S flexneri, and S boydii-that is subgroups A, B, and C-in patients in England and Wales are often acquired abroad, and the incidence of such infections has not decreased in recent years. In contrast, S sonnei-that is subgroup D-is indigenous but its incidence has decreased considerably since the 1960s when it accounted for more than 90% of all shigella infections. As a result infections caused by subgroups A, B, and C accounted for one quarter of all shigella infections reported to the Communicable Disease Surveillance Centre in England and Wales during the period 1979-82. We have previously reported that the incidence of drug resistance in members of shigella subgroups A, B, and C increased rapidly during the period while that in S sonnei decreased.' In particular, the incidence of resistance to sulphonamides, streptomycin, tetracycines, ampicillin, and chloramphenicol increased. We report the incidence of drug resistance in these organisms during the period 1979 to mid-1983 and note in particular the appearance of appreciable numbers of strains resistant to trimethoprim.
Methods
Bacterial strains-During the period 1979 to mid-1983 2753 strains of S dysenteriae, S flexneri, and S boydii isolated in England and Wales from human faeces were examined in the Division of Enteric Pathogens, Central Public Health Laboratory, London. S sonnei strains are not referred to this laboratory. All the strains were identified as members of the genus shigella by the methods of Edwards and Ewing2 and were serotyped according to the internationally accepted scheme.3
Drug resistance tests-Initial screening for resistance to ampicillin, chloramphenicol, gentamicin, neomycin or kanamycin, streptomycin, and tetracyclines was performed by a strip diffusion method.4 Strains found to be resistant by this method were further tested by an agar dilution method.5 Resistance to sulphonamides, trimethoprim, furazolidone, and nalidixic acid was also tested by the agar dilution method. Table I shows the drug concentrations used in the agar dilution tests. (1-8%) . In 15 of 28 strains with transferable trimethoprim resistance (53 6%), the plasmids that conferred resistance to trimethoprim did not specify resistance to other antibiotics; in 13 strains (46-4%) trimethoprim resistance was cotransferred with resistance to other antibiotics. In the strain with resistance able to be mobilised, the trimethoprim resistance plasmid also conferred resistance to sulphonamides. An account of these plasmids will be presented elsewhere.
We have previously suggested that the increase in resistance to ampicillin, chloramphenicol, streptomycin, sulphonamides, and tetracyclines might be due to the use of the respective antimicrobial drugs in countries other than Britain.' With this in mind, the incidence of foreign travel, or contact with recent travellers, among patients with strains resistant to trimethoprim was compared with that among patients with strains sensitive to trimethoprim (table III) . Significantly fewer patients with strains resistant to trimethoprim had recently travelled abroad or had been in contact with recent travellers (X2=24-1, p<0-001).
Discussion
Epidemics of bacillary dysentery, especially those caused by S dysenteriae 1 (Shiga's bacillus), continue to occur in tropical attention to the sudden increase in the incidence of ampicillin resistance. Ampicillin is widely regarded as the drug of choice for the treatment of severe bacillary dysentery and is used routinely in many countries. We have suggested that the rapid increase in drug resistance observed in strains isolated in Britain might be the result of the uncontrolled use of antibiotics in certain developing countries. In the present study we have seen a continuing rise in the incidence of resistance to ampicillin, chloramphenicol, and tetracycline among strains of shigella subgroups A, B, and C isolated in Britain during the period 1979 to mid-1983. In addition, a sudden increase in the incidence of trimethoprim resistance occurred-an important finding as trimethoprim is regarded as the drug of choice for the treatment of bacillary dysentery caused by strains resistant to ampicillin. In this case, however, the statistical evidence does not support the suggestion that trimethoprim resistance has arisen entirely as a result of the use of antibiotics in other countries. Notably fewer patients with strains resistant to trimethoprim had a history of foreign travel or contact with travellers than did patients with strains sensitive to trimethoprim. Furthermore, the increase in trimethoprim resistance coincided with products containing trimethoprim but not sulphonamides becoming available in Britain. In this respect it may be important that more than half of the trimethoprim resistance plasmids identified conferred resistance to trimethoprim but not to sulphonamides. Co-trimoxazole resistance, however, has recently been observed in family outbreaks of S dysenteriae 1 in rural Bangladesh, and the overuse of antibiotics by local practitioners in that country has been suggested as a contributory factor.12 Thus it must be considered that the use of products containing trimethoprim in both Britain and developing countries has led to the increased incidence of trimethoprim resistance in shigella strains isolated in Britain.
Although bacillary dysentery is often a mild, self limiting disease in otherwise healthy subjects, the severe symptoms and high mortality seen in epidemics in the tropics indicate that prompt antibiotic treatment may be life saving, particularly in the very young, the very old, and the malnourished. In such circumstances it may be necessary to begin treatment without the benefit of the results of in vitro sensitivity tests. In the central African epidemic the causative organisms were resistant to ampicillin, and treatment with co-trimoxazole was consequently adopted and found to be effective in reducing mortality. Nevertheless, resistance to trimethoprim was rapidly acquired as the epidemic progressed, presumably in response to selective pressures imposed by the use of co-trimoxazole.13 Treatment with nalidixic acid was subsequently introduced, but the impact of this on fatality has not yet been evaluated. The need for antibiotic treatment of patients in Britain can only be assessed individually on clinical grounds. The rapidly increasing range of drug resistance among the shigella strains studied underlines the value of performing in vitro sensitivity tests before starting antibiotic treatment whenever possible. The choice of antibiotic for initial treatment without benefit of such tests is becoming increasingly restricted.
In a patient with a family history of malignant hyperthermia does a normal muscle biopsy specimen give 100% assurance that that patient will not have a hyperthermic reaction?
Muscle biopsy followed by pharmacological testing of living muscle tissue in vitro has become the preferred method of screening members of families with malignant hyperpyrexia for susceptibility. Until recently each laboratory used its own test regimen and applied its own criteria before making the diagnosis; most investigators admitted to nominating an equivocal result to be susceptible and thereby increasing the incidence of false positives. Standardisation of the test protocol has been urged by Rosenberg' and 
